ZVRA (Kempharm) Net earnings per share (EPS TTM)

Kempharm (ZVRA) - corporate logo

This current EPS (TTM) chart for Zevra Therapeutics (ZVRA) reflects a value of 103.40. Zevra Therapeutics (ZVRA) complies with standard environmental regulations for laboratory research. Management is successfully transforming the business into a commercial format with a focus on profitability and the launch of Miplyffa. The cash flow is based on the sale of patented therapies for rare brain pathologies and licensing royalties for its developments.

Kempharm - ZVRA Earnings per share for the last twelve months (period 02/11/2024 - 11/18/2026)

ZVRA (Zevra Therapeutics Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:ZVRA Kempharm
Flagship merchandise of Zevra Therapeutics, Inc.

Zevra Therapeutics (ZVRA) maintains a high reputation as a developer of drugs for the treatment of rare neurological pathologies. Analyzing the current EPS YoY TTM trajectory, an investor can see the percentage change in earnings per share over a rolling year. This metric compares the aggregate income of the last twelve months with the same period last year, neutralizing quarterly volatility. The positive trend confirms the effectiveness of the commercialization of orphan drugs and the fundamental stability of the asset.